Adhera Therapeutics, Inc. (ATRX)
Stock Price:
$0.101 USD
0.011 (12.22%)
Updated Aug 11, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
1.10M |
| Revenue (ttm) |
249,000 |
| Net Income (ttm) |
-11.26M |
| Shares Out |
10.87M |
| EPS (ttm) |
-1.18 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 11, 2020 |
| Last Price |
$0.101 |
| Previous Close |
$0.090 |
| Change ($) |
0.011 |
| Change (%) |
12.22% |
| Day's Open |
0.070 |
| Day's Range |
0.070 - 0.101 |
| Day's Volume |
12,451 |
| 52-Week Range |
0.020 - 0.300 |
More Stats
| Market Cap |
1.10M |
| Enterprise Value |
6.83M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
10.87M |
| Float |
7.27M |
| EPS (basic) |
-1.17 |
| EPS (diluted) |
-1.18 |
| FCF / Share |
-0.65 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
40,932 |
| Short Ratio |
3.24 |
| Short % of Float |
3.93% |
| Beta |
1.44 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
4.41 |
| PB Ratio |
n/a |
| Revenue |
249,000 |
| Operating Income |
-10.08M |
| Net Income |
-11.26M |
| Free Cash Flow |
-7.04M |
| Net Cash |
-5.73M |
| Net Cash / Share |
-0.53 |
| Gross Margin |
-63.05% |
| Operating Margin |
-4,048.59% |
| Profit Margin |
-5,124.50% |
| FCF Margin |
-2,828.19% |
| ROA |
-312.67% |
| ROE |
-2,977.88% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
400
Current: $0.101
High
400
Target: 400.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 0.25 | 0.08 | - | - | - | 0.50 | 2.12 | 4.22 | 2.24 | 2.46 |
| Revenue Growth | 231.58% | - | - | - | - | -76.36% | -49.85% | 88.6% | -9.11% | - |
| Gross Profit | -0.16 | -0.21 | - | - | - | 0.50 | 2.12 | 4.22 | 2.24 | 2.46 |
| Operating Income | -11.32 | -15.80 | -6.09 | -0.76 | -1.11 | -3.52 | -0.37 | -7.88 | -35.00 | -29.53 |
| Net Income | -11.98 | -16.76 | -6.22 | -0.84 | -1.11 | -6.48 | -1.57 | -9.55 | -29.42 | -27.75 |
| Shares Outstanding | 10.84 | 10.84 | 9.84 | 47.43 | 0.29 | 2.46 | 1.69 | 1.34 | 0.63 | 0.18 |
| Earnings Per Share | -1.24 | -1.64 | -0.63 | -0.02 | -3.80 | -5.10 | -0.90 | -7.10 | -46.50 | -158.00 |
| Operating Cash Flow | -8.74 | -9.61 | -1.26 | -0.52 | -0.74 | -4.78 | 0.29 | -4.39 | -16.12 | -16.80 |
| Capital Expenditures | - | -0.07 | - | - | - | - | 0.03 | 0.43 | - | -0.40 |
| Free Cash Flow | -8.74 | -9.69 | -1.26 | -0.52 | -0.74 | -4.78 | 0.32 | -3.96 | -16.12 | -17.21 |
| Cash & Equivalents | 0.05 | 3.92 | 0.11 | 0.11 | 0.26 | 1.82 | 0.91 | 0.60 | 1.99 | 2.08 |
| Total Debt | 5.33 | - | 1.91 | 0.69 | - | - | 1.62 | 1.45 | - | - |
| Net Cash / Debt | -5.28 | 3.92 | -1.80 | -0.58 | 0.26 | 1.82 | -0.71 | -0.85 | 1.99 | 2.08 |
| Assets | 0.42 | 5.14 | 6.18 | 6.19 | 0.26 | 9.22 | 7.74 | 7.45 | 11.75 | 29.44 |
| Liabilities | 10.31 | 2.21 | 5.74 | 2.97 | 0.17 | 13.59 | 14.81 | 13.08 | 11.71 | 12.27 |
| Book Value | -9.89 | 2.93 | 0.45 | 3.22 | 0.09 | -4.37 | -7.06 | -5.63 | 0.04 | 17.17 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Adhera Therapeutics, Inc. |
| Country |
United States |
| Employees |
2 |
| CEO |
Andrew Albert Kucharchuk |
Stock Information
| Ticker Symbol |
ATRX |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: ATRX |
Description
Adhera Therapeutics, Inc., a specialty pharmaceutical company, engages in the development and commercialization of drug therapeutics for chronic and acute diseases in the United States. It markets Prestalia, a single-pill fixed dose combination of perindopril argenine, an ACE inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is headquartered in Wake Forest, North Carolina.